The present invention relates to the use of 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S- methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4- Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-l,3,5-triazin-2-amine (compound A), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.